Drug Profile
Research programme: small molecule therapeutics - Sanofi/ X-Chem
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Sanofi; X-Chem
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Metabolic disorders
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Cancer in USA
- 28 Feb 2020 No recent reports of development identified for research development in Metabolic-disorders in USA
- 06 Jan 2016 Sanofi and X-chem agree to co-develop small molecule therapeutics in USA for cancer, rare disorders and metabolic disorders